Your session is about to expire
← Back to Search
Demeclocycline for Brain Tumor
Phase 1
Waitlist Available
Led By William T Curry, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Summary
This research study is studying a drug called Demeclocycline that may help brain surgeons see tumors with a microscope during surgery.
Eligible Conditions
- Brain Tumor
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Detectable fluorescence in brain tumors by confocal microscopy after oral dosing of demeclocycline (Y/N).
Secondary study objectives
Sensitivity And Specificity Of Demeclocycline-Enhanced Multimodal Confocal Microscopy of Excised Glioma Specimens
Side effects data
From 2014 Phase 4 trial • 69 Patients • NCT0175385611%
Constipation
11%
Post procedural discomfort
11%
Contusion
6%
Nasopharyngitis
6%
Rash
3%
Pain in extremity
3%
Appendicitis
3%
Deep vein thrombosis
3%
Diarrhoea
3%
Hypokalaemia
3%
Arthralgia
3%
Tremor
3%
Pruritus
3%
Skin induration
3%
Bronchitis
3%
Fatigue
3%
Cough
3%
Groin pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Denosumab
Teriparatide
Trial Design
1Treatment groups
Experimental Treatment
Group I: DemeclocyclineExperimental Treatment1 Intervention
All subjects will take Demeclocycline 300 mg po bid. Patients will be advised to take demeclocycline on an empty stomach, at least 1-2 hours before meals, and they will be warned that it can reduce the efficacy of oral contraceptives.
The investigators will begin by treating subjects with 2 days of demeclocycline. The investigators will increase the numbers of days that subjects are exposed to demeclocycline in increments of 1 day until at least 80% of patients at a given dose have detectably fluorescent tumors, or participants reach 5 days of drug, whichever comes first.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Demeclocycline
FDA approved
Find a Location
Who is running the clinical trial?
Massachusetts General HospitalLead Sponsor
2,993 Previous Clinical Trials
13,230,681 Total Patients Enrolled
William T Curry, MDPrincipal InvestigatorMassachusetts General Hospital
Share this study with friends
Copy Link
Messenger